MedTrace Logo

The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

NCT01268163 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-03-20

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetic and safety characteristics of European Taxotere® and American Taxotere® with Hospira Docetaxel injection in patients with cancer.

Conditions

Interventions

DRUG

European Taxotere®

60-100 mg/m\^2 IV

DRUG

American Taxotere®

60-100 mg/m\^2 IV

DRUG

Hospira Docetaxel Injection

60-100 mg/m\^2 IV

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • M. Ranson · Christie Hospital, Manchester

  • V Semiglazov · N.N. Petrov Research Institute of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01268163 on ClinicalTrials.gov